Molecular pathways and related target therapies in liver carcinoma

Research output: Contribution to journalArticlepeer-review

Abstract

Hepatocellular carcinoma (HCC) is a frequent neoplasia which still misses a therapeutical gold standard. Recently, new acquisitions in cancerogenesis process evidenced the genetic and epigenetic alterations of genes involved in the different metabolic pathways of liver cancer suggesting that antibodies, small molecules, demethylating agents, etc. specifically acting against molecular target can be utilized alone or in combination in clinical practice. The main altered targets are: cell membrane receptors, in particular tyrosine kinase receptors, factors involved in cell signalling, specifically Wnt/β-catenin, Ras/Raf/ MEK/ERK and P13K/Akt/mTOR pathways, proteins linked to cell cycle regulation pathway (i.e. p53, p16/INK4, cyclin/cdk complex) or in invasiveness (EMT, TGFbeta) and proteins involved in DNA metabolism. Genetic or epigenetic changes in these molecules have been used in preclinical settings and, some of them also in clinical trials of phase II and III. This scenario opens new avenues for the prevention and the treatment of HCC. In the present review the main metabolic pathways and molecular alterations have been described together with recent advances in molecular and gene therapy.

Original languageEnglish
Pages (from-to)3279-3287
Number of pages9
JournalCurrent Pharmaceutical Design
Volume13
Issue number32
DOIs
Publication statusPublished - Nov 2007

Keywords

  • Cellular pathways
  • Hepatocarcinoma
  • Molecular alterations
  • Target therapies

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Molecular pathways and related target therapies in liver carcinoma'. Together they form a unique fingerprint.

Cite this